Evidence map›Paper›PMID 39679456›Full record

ReviewChinese medical journal2024

Nanomedicine: The new trend and future of precision medicine for inflammatory bowel disease.

Huanyu Li, Meng Pan, Yifan Li, Hao Liang, Manli Cui, Mingzhen Zhang, Mingxin Zhang

Abstract readReview
In one paragraph

Review in Chinese medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Huanyu LiSecond Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China.
Meng PanSchool of Basic Medical Sciences, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China.
Yifan LiSecond Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, China.
Hao LiangDepartment of Gastroenterology, The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710077, China.
Manli CuiDepartment of Gastroenterology, The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710077, China.
Mingzhen ZhangSchool of Basic Medical Sciences, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
Mingxin ZhangDepartment of Gastroenterology, The First Affiliated Hospital of Xi'an Medical University, Xi'an, Shaanxi 710077, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

abstractNanomedicine is an interdisciplinary area that utilizes nanoscience and technology in the realm of medicine. Rapid advances in science and technology have propelled the medical sector into a new era. The most commonly used nanotechnology in the field of medicine is nanoparticles. Due to their unique physicochemical properties, nanoparticles offer significant benefits of precision medicine for diseases such as inflammatory bowel disease that cannot be effectively treated by existing approaches. Nanomedicine has emerged as a highly active research field, with extensive scientific and technological studies being carried out, as well as growing international competition in the commercialization of this field. The accumulation of expertise in the key technologies relating to nanomedicine would provide strategic advantages in the development of cutting-edge medical techniques. This review presented a comprehensive analysis of the primary uses of nanoparticles in medicine, including recent advances in their application for the diagnosis and treatment of inflammatory bowel disease. Furthermore, we discussed the challenges and possibilities associated with the application of nanoparticles in clinical settings.

Indexed as

Inflammatory Bowel DiseasesNanomedicineNanoparticlesPrecision MedicineHumans

Identifiers

PMID39679456
PMCPMC11706594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.